|
CN110003066B
(zh)
|
2013-11-18 |
2021-09-03 |
阿克丘勒斯治疗公司 |
用于rna递送的可电离的阳离子脂质
|
|
US11028388B2
(en)
|
2014-03-05 |
2021-06-08 |
Editas Medicine, Inc. |
CRISPR/Cas-related methods and compositions for treating Usher syndrome and retinitis pigmentosa
|
|
EP3540061A1
(en)
|
2014-04-02 |
2019-09-18 |
Editas Medicine, Inc. |
Crispr/cas-related methods and compositions for treating primary open angle glaucoma
|
|
RU2019121801A
(ru)
|
2016-12-14 |
2021-01-15 |
Лигандал, Инк. |
Композиции и способы для доставки полезной нагрузки в виде нуклеиновой кислоты и/или белка
|
|
US10526284B2
(en)
|
2016-12-21 |
2020-01-07 |
Arcturus Therapeutics, Inc. |
Ionizable cationic lipid for RNA delivery
|
|
WO2018119163A1
(en)
*
|
2016-12-21 |
2018-06-28 |
Payne Joseph E |
Ionizable cationic lipid for rna delivery
|
|
US10383952B2
(en)
*
|
2016-12-21 |
2019-08-20 |
Arcturus Therapeutics, Inc. |
Ionizable cationic lipid for RNA delivery
|
|
US20200046830A1
(en)
|
2017-03-30 |
2020-02-13 |
The Government Of The United States, As Represented By The Secretary Of The Army |
Nucleic acid vaccine composition comprising a lipid formulation, and method of increasing the potency of nucleic acid vaccines
|
|
US11015204B2
(en)
*
|
2017-05-31 |
2021-05-25 |
Arcturus Therapeutics, Inc. |
Synthesis and structure of high potency RNA therapeutics
|
|
WO2019191780A1
(en)
*
|
2018-03-30 |
2019-10-03 |
Arcturus Therapeutics, Inc. |
Lipid particles for nucleic acid delivery
|
|
JP7256824B2
(ja)
|
2018-04-25 |
2023-04-12 |
エスリス ゲーエムベーハー |
粒子状製剤用の凍結保護剤
|
|
KR20190127277A
(ko)
*
|
2018-05-04 |
2019-11-13 |
주식회사 삼양바이오팜 |
mRNA 전달용 고분자 나노입자 조성물 및 그 제조방법
|
|
ES2964547T3
(es)
|
2018-06-08 |
2024-04-08 |
Fujifilm Corp |
Compuesto, sal del mismo y partículas lipídicas
|
|
CA3122080A1
(en)
|
2018-12-06 |
2020-06-11 |
Arcturus Therapeutics, Inc. |
Compositions and methods for treating ornithine transcarbamylase deficiency
|
|
EP3942050A4
(en)
|
2019-03-19 |
2023-02-22 |
Arcturus Therapeutics, Inc. |
PROCEDURE FOR THE PRODUCTION OF LIPID-COATED RNA NANOPARTICLES
|
|
CA3143865A1
(en)
|
2019-06-07 |
2020-12-10 |
Fujifilm Corporation |
Lipid composition
|
|
WO2021067598A1
(en)
|
2019-10-04 |
2021-04-08 |
Ultragenyx Pharmaceutical Inc. |
Methods for improved therapeutic use of recombinant aav
|
|
EP4059505B1
(en)
|
2019-11-15 |
2024-02-21 |
FUJIFILM Corporation |
Lipid composition
|
|
EP4114470A4
(en)
|
2020-03-03 |
2024-04-17 |
Arcturus Therapeutics, Inc. |
COMPOSITIONS AND METHODS FOR TREATING ORNITHINE TRANSCARBAMYLASE DEFICIENCY
|
|
IL296660A
(en)
|
2020-03-24 |
2022-11-01 |
Generation Bio Co |
Non-viral DNA vectors and their use for therapeutic expression of factor ix
|
|
IL296662A
(en)
|
2020-03-24 |
2022-11-01 |
Generation Bio Co |
Non-viral dna vectors and uses thereof for expressing gaucher therapeutics
|
|
US20230227826A1
(en)
*
|
2020-06-18 |
2023-07-20 |
Arcturus Therapeutics, Inc. |
Una oligomers for the treatment of polyglutamine diseases
|
|
MX2023001109A
(es)
|
2020-07-27 |
2023-04-24 |
Anjarium Biosciences Ag |
Composiciones de moleculas de adn, metodos para elaborar las mismas, y metodos de usos de las mismas.
|
|
IL301253A
(en)
|
2020-09-13 |
2023-05-01 |
Arcturus Therapeutics Inc |
As a mass of large RNA lipid nanoparticles
|
|
TWI918825B
(zh)
|
2021-02-10 |
2026-03-21 |
美商艾勒維生技公司 |
化合物、組合物及其使用方法
|
|
JP2024517427A
(ja)
|
2021-04-20 |
2024-04-22 |
アンジャリウム バイオサイエンシズ エージー |
アミロ-α-1,6-グルコシダーゼ、4-α-グルカノトランスフェラーゼをコードするDNA分子の組成物、その作製の方法、及びその使用の方法
|
|
JP2024515788A
(ja)
|
2021-04-27 |
2024-04-10 |
ジェネレーション バイオ カンパニー |
治療抗体を発現する非ウイルスdnaベクター及びその使用
|
|
US20240216535A1
(en)
|
2021-04-27 |
2024-07-04 |
Generation Bio Co. |
Non-viral dna vectors expressing anti-coronavirus antibodies and uses thereof
|
|
EP4763287A2
(en)
|
2021-09-03 |
2026-06-24 |
CureVac SE |
Novel lipid nanoparticles for delivery of nucleic acids
|
|
EP4422698A1
(en)
|
2021-10-29 |
2024-09-04 |
CureVac SE |
Improved circular rna for expressing therapeutic proteins
|
|
WO2023081526A1
(en)
|
2021-11-08 |
2023-05-11 |
Orna Therapeutics, Inc. |
Lipid nanoparticle compositions for delivering circular polynucleotides
|
|
JP2024546431A
(ja)
|
2021-11-11 |
2024-12-24 |
アークトゥラス・セラピューティクス・インコーポレイテッド |
Rna送達のためのイオン化可能なカチオン性脂質
|
|
WO2023135273A2
(en)
|
2022-01-14 |
2023-07-20 |
Anjarium Biosciences Ag |
Compositions of dna molecules encoding factor viii, methods of making thereof, and methods of use thereof
|
|
EP4469091A1
(en)
|
2022-01-28 |
2024-12-04 |
CureVac SE |
Nucleic acid encoded transcription factor inhibitors
|
|
CN114213295B
(zh)
*
|
2022-02-22 |
2022-05-20 |
中国科学院基础医学与肿瘤研究所(筹) |
一种阳离子化合物、制备方法及其复合物和用途
|
|
EP4493212A1
(en)
|
2022-03-14 |
2025-01-22 |
Generation Bio Co. |
Heterologous prime boost vaccine compositions and methods of use
|
|
CA3248209A1
(en)
|
2022-05-25 |
2023-11-30 |
CureVac SE |
Escherichia coli Antigenic Polypeptide-Based Nucleic Acid Vaccine (FIMH)
|
|
WO2023239756A1
(en)
|
2022-06-07 |
2023-12-14 |
Generation Bio Co. |
Lipid nanoparticle compositions and uses thereof
|
|
WO2024040222A1
(en)
|
2022-08-19 |
2024-02-22 |
Generation Bio Co. |
Cleavable closed-ended dna (cedna) and methods of use thereof
|
|
KR20250110209A
(ko)
|
2022-09-23 |
2025-07-18 |
엔크로마 바이오, 인크. |
Hbv 유전자 발현의 에피제네틱 조절을 위한 조성물 및 방법
|
|
WO2024089638A1
(en)
|
2022-10-28 |
2024-05-02 |
Glaxosmithkline Biologicals Sa |
Nucleic acid based vaccine
|
|
WO2024102762A1
(en)
|
2022-11-08 |
2024-05-16 |
Orna Therapeutics, Inc. |
Lipids and lipid nanoparticle compositions for delivering polynucleotides
|
|
WO2024102730A1
(en)
|
2022-11-08 |
2024-05-16 |
Orna Therapeutics, Inc. |
Lipids and nanoparticle compositions for delivering polynucleotides
|
|
TW202428289A
(zh)
|
2022-11-08 |
2024-07-16 |
美商歐納醫療公司 |
環狀rna組合物
|
|
JP2025541726A
(ja)
|
2022-12-01 |
2025-12-23 |
ジェネレーション バイオ カンパニー |
細胞標的化のためのステルス脂質ナノ粒子組成物
|
|
AU2023406321A1
(en)
|
2022-12-01 |
2025-05-29 |
Generation Bio Co. |
Novel polyglycerol-conjugated lipids and lipid nanoparticle compositions comprising the same
|
|
EP4626402A1
(en)
|
2022-12-01 |
2025-10-08 |
Generation Bio Co. |
Lipid nanoparticles comprising nucleic acids and lipid-anchored polymers
|
|
US20260207525A1
(en)
|
2022-12-01 |
2026-07-23 |
Generation Bio Co. |
Lipid nanoparticles comprising nucleic acids, ionizable lipids, sterols, lipid anchored polymers and helper lipids, their uses
|
|
KR20250153298A
(ko)
|
2023-03-08 |
2025-10-24 |
큐어백 에스이 |
핵산 전달을 위한 신규의 지질 나노입자 제형
|
|
WO2024205657A2
(en)
|
2023-03-29 |
2024-10-03 |
Orna Therapeutics, Inc. |
Lipids and lipid nanoparticle compositions for delivering polynucleotides
|
|
WO2024233308A2
(en)
|
2023-05-05 |
2024-11-14 |
Orna Therapeutics, Inc. |
Circular rna compositions and methods
|
|
WO2024230934A1
(en)
|
2023-05-11 |
2024-11-14 |
CureVac SE |
Therapeutic nucleic acid for the treatment of ophthalmic diseases
|
|
JP2026523341A
(ja)
|
2023-05-15 |
2026-07-14 |
エヌクロマ・バイオ,インコーポレーテッド |
Hbv遺伝子発現のエピジェネティック調節のための組成物および方法
|
|
CN116270543B
(zh)
*
|
2023-05-19 |
2023-09-26 |
清华大学 |
脂质纳米颗粒在制备通过雾吸或鼻滴给药递送核酸的药物中的用途
|
|
EP4719352A1
(en)
|
2023-05-31 |
2026-04-08 |
Capstan Therapeutics, Inc. |
Lipid nanoparticle formulations and compositions
|
|
WO2025049690A1
(en)
|
2023-08-29 |
2025-03-06 |
Orna Therapeutics, Inc. |
Circular polyethylene glycol lipids
|
|
CN117986153B
(zh)
|
2023-09-07 |
2026-06-19 |
晟迪生物医药(苏州)有限公司 |
一种可电离阳离子脂质化合物及其制备方法和应用
|
|
WO2025052180A2
(en)
|
2023-09-07 |
2025-03-13 |
Axelyf ehf. |
Lipids and lipid nanoparticles
|
|
EP4791878A1
(en)
|
2023-10-13 |
2026-08-19 |
Ultragenyx Pharmaceutical Inc. |
Compositions and methods for treating conditions associated with cartilage oligomeric matrix protein (comp) mutations
|
|
CN122497525A
(zh)
|
2023-11-07 |
2026-07-31 |
欧纳医疗公司 |
环状rna组合物
|
|
AU2024397279A1
(en)
|
2023-12-13 |
2026-07-02 |
Ultragenyx Pharmaceutical Inc. |
Compositions and methods for treating conditions associated with ube3a overexpression
|
|
IL328626A
(en)
|
2023-12-15 |
2026-07-01 |
Capstan Therapeutics Inc |
Humanized anti-CD8 antibodies and their uses
|
|
AU2025217182A1
(en)
|
2024-02-02 |
2026-08-06 |
Editas Medicine, Inc. |
MODIFIED GUIDE RNAs
|
|
US20250381150A1
(en)
|
2024-03-08 |
2025-12-18 |
Genzyme Corporation |
Lipid nanoparticles
|
|
WO2025213138A1
(en)
|
2024-04-05 |
2025-10-09 |
Editas Medicine, Inc. |
Crispr/rna-guided nuclease related methods and compositions for treating primary open angle glaucoma
|
|
WO2026003582A2
(en)
|
2024-06-27 |
2026-01-02 |
Axelyf ehf. |
Lipids and lipid nanoparticles
|
|
WO2026030375A2
(en)
|
2024-07-30 |
2026-02-05 |
Genzyme Corporation |
Lipid nanoparticles and methods of manufacture and use thereof
|
|
WO2026064512A1
(en)
|
2024-09-18 |
2026-03-26 |
Generation Bio Co. |
Polyglycerol-conjugated lipids and lipid nanoparticle compositions comprising the same
|
|
WO2026085495A1
(en)
|
2024-10-18 |
2026-04-23 |
Generation Bio Co. |
Synthetic partially single-stranded nucleic acid compositions and uses and methods therefor
|
|
WO2026102260A1
(en)
|
2024-11-08 |
2026-05-15 |
Editas Medicine, Inc. |
Crispr-related methods and compositions targeting angiopoietin like 3 (angptl3)
|
|
WO2026142951A1
(en)
|
2024-12-23 |
2026-07-02 |
Genzyme Corporation |
Pharmaceutical system
|